Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="107950" type="General" weightage="20" keywordseo="artificial-intelligence" source="Orion">Artificial intelligence</keyword> (<keyword id="19899640" type="General" weightage="100" keywordseo="AI" source="keywords">AI</keyword>) has taken the world by storm. Since the release of OpenAI’s <keyword id="19918826" type="General" weightage="20" keywordseo="ChatGPT" source="keywords">ChatGPT</keyword> in 2022, discussions have ranged from optimistic visions of a utopian future to pessimistic fears of threats posed by technology to humanity itself. But no matter what, it's undeniable that AI has captured everyone’s attention. However, in spite of all the hype, very few people around the world are actually making use of AI on a regular basis, a survey has found. <cmsannotation type="cmsannotation" annotationid="Bursting the bubble: The divide between AI hype and everyday use" comment="subhead" text="Bursting the bubble: The divide between AI hype and everyday use">Bursting the bubble: The divide between <keyword id="21872732" type="General" weightage="20" keywordseo="AI-hype" source="Orion">AI hype</keyword> and everyday use</cmsannotation> <keyword id="19896272" type="General" weightage="20" keywordseo="generative-AI" source="keywords">Generative AI</keyword> — a technology that produces human-like outputs such as text, images, audio or video based on input prompts — burst onto the public scene with the launch of ChatGPT in November 2022. This sparked a frenzied competition among tech giants, who have since invested billions into developing their own generative AI capabilities. However, research suggests that despite the substantial investment and attention, generative AI has yet to integrate seamlessly into everyday internet use. The <a href="https://reutersinstitute.politics.ox.ac.uk/what-does-public-six-countries-think-generative-ai-news#header--3">online survey</a>, conducted by the <keyword id="21872733" type="General" weightage="20" keywordseo="reuters-institute" source="keywords">Reuters Institute</keyword> and <keyword id="19897709" type="General" weightage="20" keywordseo="oxford-university" source="keywords">Oxford University</keyword>, surveyed 12,000 individuals across six countries — Argentina, Denmark, France, Japan, the UK, and the USA — to explore perceptions of generative AI tools. Despite relatively high awareness of ChatGPT compared to other generative AI tools, the survey found that only an average of 54% of respondents across the six countries had heard of it. Even among those aware, the majority reported limited or no usage, with only about 3% using the tool daily. Usage patterns varied by demographics, with men and individuals with higher education levels more likely to use ChatGPT. However, the most significant disparities were observed by age group, with younger individuals aged 18 to 24 exhibiting higher usage rates, albeit predominantly infrequent. The study also sought to understand public perceptions of generative AI's societal impact. While many respondents anticipate significant contributions to fields like news, media and science, the overall sentiment was cautiously optimistic, with concerns about the technology's broader societal implications. <cmsannotation type="cmsannotation" annotationid="The trough of disillusionment" comment="subhead" text="The trough of disillusionment">The <keyword id="21872734" type="General" weightage="20" keywordseo="trough-of-disillusionment" source="Orion">trough of disillusionment</keyword></cmsannotation> The findings of this online international survey highlight a notable disparity between the hype surrounding AI and public engagement with it. This phenomenon, where the technology is heavily hyped but the practical application and adoption lag behind, mirrors the concept of the “trough of disillusionment” described in the Gartner Hype Cycle. The “trough of disillusionment” signifies a phase in the technology lifecycle where inflated expectations meet the reality of practical limitations, leading to a decline in enthusiasm. Despite this disillusionment, the phase also marks an opportunity for deeper understanding and practical application of the technology. At the moment, the adoption of AI and related technologies appears to be widespread across technology and media companies, compared to individuals. However, the discourse around the topic varies within a wide spectrum of ideas ranging from ‘technological determinism’ (the idea where technologies shape human societies) to ‘social constructivism’ (where our social behaviour shapes technological advancement). In some cases, the ‘trough of disillusionment’ phase is followed by the ‘slope of enlightenment’, This represents a pivotal phase where the benefits of the technology become clearer, driving increased adoption and investment. It heralds a transition from hype to tangible outcomes, laying the groundwork for broader integration and innovation. Will this be the case with generative AI as well? Only time will tell.

Despite the hype, AI tools like ChatGPT remain dormant in daily use, shows global survey

Have you ever seen someone so pressed and angry that you seriously considered throwing some holy water at them? We think it’s safe to say that the jury’s still out on whether this will actually calm them down, considering common sense dictates that splashing water at a mad person can make them madder. But in the meantime, you might want to consider slipping some omega-3 capsules into their food instead. Omega-3 <keyword id="1576081" type="General" weightage="20" keywordseo="fish-oil-supplements" source="Orion">fish oil supplements</keyword> have been all the rage in recent decades. Whether it’s for your heart health or reproductive, the list of apparent benefits of this humble little compound never seems to end. More recently, researchers from the University of Pennsylvania found that these commonplace supplements can effectively lower aggression levels, regardless of age or gender. The <a href="https://www.sciencedirect.com/science/article/abs/pii/S1359178924000466">study</a>, led by neurocriminologist Adrian Raine, analysed 29 randomised controlled trials that examined the effects of omega-3 supplementation on aggression. The results were promising, revealing a modest yet significant reduction in both reactive and proactive aggression. <h2>The science behind omega-3</h2><keyword id="19923746" type="General" weightage="20" keywordseo="omega-3-fatty-acids" source="keywords">Omega-3 fatty acids</keyword>, commonly found in fish like salmon, mackerel, and sardines, are essential for brain structure and function. They play a critical role in maintaining the fluidity of cell membranes, which is vital for efficient communication between neurons. More specifically, omega-3s are involved in regulating neurotransmitters — chemical messengers in the brain — like dopamine and serotonin, both of which are crucial in mood regulation and impulse control. <keyword id="22915070" type="General" weightage="20" keywordseo="aggressive-behaviour" source="keywords">Aggressive behaviour</keyword> has been linked to dysfunctions in these neurochemical systems. For instance, lower levels of serotonin have been associated with increased impulsivity and aggression, while dopamine imbalances can affect the brain's reward system, which may contribute to proactive aggression. Omega-3 supplementation is believed to help stabilise these neurotransmitters, which in turn may reduce the likelihood of aggressive outbursts. Another reason omega-3s might <keyword id="23427821" type="General" weightage="20" keywordseo="reduce-aggression" source="keywords">reduce aggression</keyword> is their anti-inflammatory properties. Chronic inflammation in the brain can disrupt normal cognitive and emotional processing, leading to heightened aggression and irritability. Omega-3s are known to reduce brain inflammation, which could improve <keyword id="20068883" type="General" weightage="20" keywordseo="brain-function" source="keywords">brain function</keyword> and reduce aggression by restoring normal neurobiological pathways. <div type="Article" hostid="261" msid="105077491" title="A longevity expert shares the supplements he takes to support his &amp;#39;vegan plus fish&amp;#39; diet that he says will help him live longer" mstype="2" mssubtype="0"></div> <h2>From prisons to society </h2>The idea that omega-3 can influence aggression isn't new. A 2002 study conducted at the <keyword id="19978045" type="General" weightage="20" keywordseo="University-of-Oxford" source="keywords" meta.keywordsubtype="org" meta.entityname="University of Oxford" meta.hostid="261" meta.entityid="University of Oxford">University of Oxford</keyword> found that prisoners who were given supplements containing omega-3 and other essential nutrients displayed significantly less violent behaviour. A 2001 study by Dr. Joseph Hibbeln of the US National Institutes of Health also found that societies consuming higher amounts of fish had lower homicide rates, further suggesting a link between omega-3 intake and reduced violence. The recent Penn study builds on this by discovering that omega-3 supplementation reduced both "reactive" and "proactive" aggression. <keyword id="23427822" type="General" weightage="20" keywordseo="reactive-aggression" source="keywords">Reactive aggression</keyword> is an emotional, in-the-moment response to a perceived threat, while proactive aggression is calculated and planned. The supplements showed a 30% reduction in both types of aggression, suggesting that omega-3s can affect different kinds of aggressive behaviour. The findings of this study have significant implications for various settings, including communities, clinics, and the criminal justice system. Omega-3 supplementation could potentially be a valuable tool in reducing violence and improving relationships. The fact that it is widely available, mostly safe and affordable certainly makes it a very attractive option. While the current study provides compelling evidence, more research is needed to fully understand the long-term effects of omega-3 supplementation on aggression. Future studies may explore the specific mechanisms through which omega-3 exerts its influence on the brain and investigate potential genetic factors that may affect its effectiveness. <div type="Article" hostid="261" msid="110365530" title="Is it time we stopped taking over-the-counter fish oil supplements?" mstype="2" mssubtype="0"></div>

Explained: Can consuming Omega-3 supplements really help reduce aggressive behaviour?

<keyword id="22782965" type="General" weightage="20" keywordseo="Ashima-Gulati" source="keywords">Ashima Gulati</keyword> is a lawyer turned <keyword id="22782966" type="General" weightage="20" keywordseo="policy-consultant" source="keywords">policy consultant</keyword> with over 7 years of experience in India's public policy arena. Starting off with a B.A.LL.B. (Hons.) from the National Law Institute University in Bhopal, Ashima kicked off her career as a securities and capital markets lawyer in Mumbai. Craving a deeper understanding of India's socio-economic landscape, she made a switch to the development and policy sector. Since her stint in Mumbai, Ashima's had quite the journey, including a two-year fellowship where she taught 70 students from a low-income community and co-founding a non-profit to improve healthcare access for marginalised communities. More recently, while Ashima was working as an independent consultant, collaborating with government, non-profit, and private organisations to build climate resilience and adaptation strategies for these groups, she went on something of a spree and applied to 10 master’s programs that combined general policy insights with climate change and sustainable development. But here’s the kicker: she got into ALL of them and bagged over USD 200,000 in <keyword id="19897091" type="General" weightage="20" keywordseo="scholarships" source="keywords">scholarships</keyword>! The impressive list of colleges and universities she got accepted into include Oxford, Columbia, <keyword id="191548" type="General" weightage="20" keywordseo="cornell" source="Orion">Cornell</keyword>, <keyword id="142498" type="General" weightage="20" keywordseo="university-of-chicago" source="Orion">University of Chicago</keyword>'s Harris School of Public Policy, The Fletcher School at Tufts University and Geneva Graduate Institute, to name a few. As Ashima prepares to leave for Oxford, where she will pursue Master of Public Policy, we got in touch with her to ask her how she managed to achieve this monumental feat. While she works towards her ever-evolving passion for public policy and sustainable development, other aspirants can probably take a page or two out of her book! Ashima attributes her success in applying to international universities to the a few unique aspects. Here are five such major factors that helped her application stand out from the crowd in her own words: Demonstrate the uniqueness of candidature through evidence “I believe it is of utmost importance to be able to substantiate the claims that one makes in their applications with respect to their profile, work experiences, leadership qualities, and most importantly, the impact that one has created in the society. Since my college days, I have maintained a detailed record of all initiatives and opportunities I have engaged in, documenting my involvement thoroughly. For my master’s applications, I included such documentation through publications, data evidence, and other relevant sources. Additionally, I encouraged my recommenders to provide evidence supporting the qualities they intended to highlight in their letters. This approach fosters transparency and credibility in the application, avoiding the use of superlatives and ensuring grounded presentation of one’s profile.” Showcase alignment with the specific program and the university “It is essential to thoroughly research and understand the focus and advantages of the specific program before drafting application essays. This ensures that you can effectively align your profile and professional experiences with the program and the university. The application should clearly demonstrate how the program’s unique features will enhance your knowledge, skills, and career goals. In my view, the applications should be highly tailored to the specific program and university to which one is applying to.” Be honest with one’s limitations and gaps in current knowledge and skill set “In my view, there has to be a demonstrated need for upskilling and applying to the program. One should be able to discuss the obstacles and hindrances one has experienced in their current profile, and a genuine need to upskill to overcome such challenges. Additionally, the application should also discuss how the program/university will help the applicant in addressing such challenges, and in helping one grow in their professional journey.” Connect with alumni and articulate well-considered future goals “Applicants should clearly outline their professional goals, both short-term and long-term, within their applications. It is important to demonstrate that you have engaged with alumni to gain insights into the opportunities provided by the program and the university. Additionally, the application should detail how the program and the university will support you in achieving these advanced goals. This approach reflects thorough research and preparation, showcasing the uniqueness of the program and university as your commitment to leveraging these opportunities effectively.” Discuss your contribution to the growth of the program/university “Many applicants overlook this aspect in their applications. It is crucial to articulate how you will contribute to the program and university both as a current student and as an alumnus. This demonstrates a strong commitment to the institution. You should describe how you plan to leverage your skills and knowledge in specific areas, such as conferences or journals, to contribute meaningfully to the institution. This reflects your genuine interest and dedication to the institute, and a mutual relationship that you wish to nurture with the institute.” While the pointers Ashima shares are undoubtedly helpful, she stresses on how its the candidate profile that matters most. You can check out her profile <a href="https://www.linkedin.com/in/ashima-gulati/?originalSubdomain=in" data-type="tilCustomLink">here</a>. Furthermore, as dedicated as Ashima is towards her cause and her <keyword id="19907717" type="General" weightage="20" keywordseo="education" source="keywords">education</keyword> at the Blavatnik School of Government, University of Oxford, she acknowledges that letting go of the financial stability that her career in law afforded her was not an easy choice to make. However, these acceptances served as affirmations that traditional notions of what a career must look like are evolving, she asserted. She now knows that taking risks in one’s career can be rewarding if done right! Going forward, Ashima is committed to using her education to advance her career in the public policy sector with the goal of contributing to the well-being and uplifting of marginalised communities, mostly by addressing the intersections of education, healthcare and climate change. And we wish her all the very best! <div type="Article" hostid="261" msid="112316410" title="I moved from the US to Germany for college. Tuition is mostly free, but I miss the American school spirit." mstype="2" mssubtype="0"></div>

This Amritsar resident got into Oxford, Columbia, Cornell, and 10 major international programs with over Rs. 1.6 crore in scholarships! She shares 5 tips for fellow applicants

India's drug regulator has allowed the export of the first produced-in-India vaccine against malaria, developed by scientists at the University of Oxford and manufactured by <keyword id="242973" type="General" weightage="20" keywordseo="Serum-Institute" source="Orion">Serum Institute</keyword> to the UK, official sources said on Thursday. The Drugs Controller General of India (DCGI) has granted permission to send two lakh doses of the vaccine. The move comes after an application was submitted by Prakash Kumar Singh, director, <keyword id="2344259" type="General" weightage="20" keywordseo="Government-and-Regulatory-Affairs" source="Orion">Government and Regulatory Affairs</keyword>, at Serum Institute of India (SII) to DCGI on September 27 seeking permission to export the vaccine against malaria, official sources told PTI. "SII has developed the vaccine against malaria under leadership of our CEO Dr Adar C Poonawalla. We have been relentlessly working to make available made-in-India and world-class vaccines against malaria to our country and world at large," an official source quoted Singh as having said in the application. Currently, only one vaccine against malaria is available globally and GSK is the manufacturer of that. The <keyword id="24212" type="General" weightage="20" keywordseo="malaria-vaccine" source="Orion">malaria vaccine</keyword> was designed at the Jenner Institute, University of Oxford, which collaborated with the SII in 2020 to manufacture and develop the jab for large- scale supply, the sources said. The vaccine trial results which included 409 children in Nanoro, Burkina Faso showed that three initial doses followed by a booster after a year gives up to 80 per cent protection against the disease, they said. The SII along with <keyword id="30725" type="General" weightage="20" keywordseo="Oxford-University" source="Orion">Oxford University</keyword> is currently doing advanced-stage trials in African countries. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/world-heart-day-2022-silent-attacks-account-for-45-of-heart-attacks-in-men-say-doctors/articleshow/94525860.cms">World Heart Day 2022: Silent attacks account for 45% of heart attacks in men say doctors</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/retail/news/reliance-retail-launches-its-premium-fashion-and-lifestyle-store-azorte/articleshow/94532914.cms">Reliance Retail’s new lifestyle store AZORTE goes high-tech with smart trial rooms, self-checkout kiosks</a>

DGCI allows Serum Institute to export malaria vaccine to UK

<keyword id="19910149" type="General" weightage="100" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword> made headlines on Tuesday as it initiated the global withdrawal of its COVID-19 vaccine. This decision comes weeks after the pharmaceutical giant acknowledged the vaccine's potential to trigger a rare side effect known as <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> (TTS). Previously, AstraZeneca had admitted in court filings that its vaccine could lead to side effects like <keyword id="21303970" type="General" weightage="20" keywordseo="blood-clots" source="keywords">blood clots</keyword> and low blood platelet counts. However, the company has now attributed its <keyword id="21572759" type="General" weightage="20" keywordseo="vaccine-withdrawal" source="Orion">vaccine withdrawal</keyword> not to the aforementioned side effects, but to an "oversupply of updated vaccines" since the pandemic. The company also announced its decision to revoke the vaccine Vaxzevria's marketing authorisations within Europe, noting that the oversupply has reduced the demand for Vaxzevria, which is no longer being produced or distributed. According to The Telegraph, AstraZeneca had submitted its application to withdraw the vaccine on March 5, and the withdrawal became effective on May 7. AstraZeneca collaborated with the University of Oxford to develop the Vaxzevria vaccine, while also partnering with the <keyword id="19897707" type="General" weightage="20" keywordseo="Serum-Institute-of-India" source="keywords" meta.keywordsubtype="org" meta.entityname="Serum Institute of India" meta.hostid="261" meta.entityid="Serum Institute of India">Serum Institute of India</keyword> (SII), the world's largest vaccine manufacturer, to supply the Covishield vaccine to the Indian government. The UK-based pharma company is currently facing <keyword id="19982808" type="General" weightage="20" keywordseo="legal-action" source="keywords">legal action</keyword> alleging that its vaccine has caused deaths and severe harm to a few of those who received it. <cmsannotation type="cmsannotation" annotationid="The lawsuits against AstraZeneca" comment="subhead" text="The lawsuits against AstraZeneca">The lawsuits against AstraZeneca</cmsannotation> Families of individuals affected by adverse vaccine reactions continue to pursue legal recourse against AstraZeneca and the Serum Institute of India. <keyword id="21513237" type="General" weightage="20" keywordseo="venugopalan-govindan" source="keywords">Venugopalan Govindan</keyword>, whose daughter Karunya passed away after receiving the Covishield vaccine, expressed his grief and criticised various parties for his daughter's death. He highlighted alleged negligence in responding to early warning signs and cited missed opportunities to prevent tragedies like his daughter's passing. Eight families across India have joined forces to seek justice, emphasising their collective determination to hold accountable those they deem responsible for the tragic loss of their loved ones. Their shared resolve underscores their commitment to achieving justice and preventing similar tragedies from occurring again, he added. In the UK, <keyword id="21472612" type="General" weightage="20" keywordseo="jamie-scott" source="keywords">Jamie Scott</keyword> took legal action last year after suffering from a blood clot and brain bleed following his vaccination in April 2021. AstraZeneca initially denied a causal link between the vaccine and this particular side-effect, but later admitted in court documents that the vaccine could cause TTS in very rare cases. As many as 51 cases have reportedly been filed against AstraZeneca in the British High Court, with affected individuals and families seeking compensation totaling an estimated £100 million. (With inputs from multiple agencies)

AstraZeneca continues to face legal action even after withdrawing its COVID vaccine! Know all about it here

New Delhi, Oct 1 (IANSlife) In recent years, there has been a significant surge in the number of Indian students seeking education abroad. This trend is driven by a desire for high-quality education, global exposure, and enhanced career prospects. However, choosing the right destination is a crucial decision that can shape one's academic and professional journey. In this article, <keyword id="18274300" type="General" weightage="80" keywordseo="shalini-lambah" source="Orion">Shalini Lambah</keyword>, the Country Head India of Migrate World, shares with IANSlife the optimal immigration destinations for Indian students, considering factors such as educational opportunities, post-graduation prospects and quality of life. The United States: The US has long been a preferred destination for Indian students. With its world-renowned universities and diverse range of programs, the US offers an array of educational opportunities. Institutions like Harvard, MIT and Stanford are renowned globally, making the US an attractive destination for those pursuing higher education in fields like technology, engineering, business, and more. Moreover, the Optional Practical Training (OPT) program allows international students to gain valuable work experience in their field of study for up to three years after graduation. This provides a pathway to H-1B visa sponsorship and, potentially, permanent residency. Canada: Canada has become increasingly popular among Indian students due to its welcoming immigration policies and quality education system. Institutions like the <keyword id="127994" type="General" weightage="80" keywordseo="university-of-toronto" source="Orion">University of Toronto</keyword> and McGill University consistently rank among the top globally. The Post-Graduation Work Permit Program (PGWPP) enables students to work in Canada for up to three years after completing their studies, enhancing their chances of permanent residency. Additionally, Canada's reputation for multiculturalism and safety makes it an attractive destination for international students seeking a diverse and inclusive environment. Australia: Australia is known for its excellent universities, such as the <keyword id="195075" type="General" weightage="80" keywordseo="university-of-sydney" source="Orion">University of Sydney</keyword> and the University of Melbourne, and its favourable post-study work visa program. The Temporary Graduate visa (subclass 485) allows international students to work in Australia for up to four years after graduation, depending on the level of study completed.The Australian job market is robust, particularly in sectors like healthcare, engineering and information technology. This, coupled with the country's high quality of life and stunning natural landscapes, makes Australia an appealing destination. United Kingdom: The UK boasts a rich academic heritage, and institutions like the <keyword id="150557" type="General" weightage="80" keywordseo="university-of-oxford" source="Orion">University of Oxford</keyword> and the University of Cambridge are globally renowned. While the UK's post-study work opportunities were somewhat limited in the past, recent changes have made it more attractive.The reintroduction of the Post-Study Work (PSW) visa, known as the "Graduate Route," allows international students to stay and work in the UK for up to two years after completing their degree (or three years for Ph.D. graduates). This has significantly improved the UK's appeal to Indian students. Germany: Germany offers a unique combination of high-quality education and affordability, particularly at the undergraduate level. Institutions like the Technical University of Munich and the <keyword id="272222" type="General" weightage="80" keywordseo="university-of-heidelberg" source="Orion">University of Heidelberg</keyword> are renowned for their engineering and technical programs. While language proficiency is crucial for certain courses, many programs are offered in English, making it accessible to international students. Germany also provides post-study work opportunities and a pathway to permanent residency for graduates. New Zealand: New Zealand is known for its welcoming environment and high-quality education system. The Post-Study Work Visa allows international students to stay in the country for up to three years after graduation, and the country's strong economy and low crime rate make it an attractive destination. New Zealand is particularly popular for courses in agriculture, environmental sciences, and tourism management, owing to its stunning natural landscapes. Singapore: Singapore has emerged as a hub for business and technology, offering a range of programs for Indian students. The country's strategic location in Asia makes it an ideal choice for those looking to immerse themselves in the region's business world. Singapore's education system is highly regarded, and various scholarships are available for international students. Additionally, the country provides a potential pathway to permanent residency for skilled professionals.

Tax-friendly destinations: A guide to the world's lowest taxes countries

<keyword id="8764262" type="General" weightage="20" keywordseo="covid" source="Orion">Covid</keyword> is unlikely to mutate into a deadlier variant and will eventually end up as a common cold, said Professor Dame Sarah Gilbert, who created the <keyword id="9605255" type="General" weightage="20" keywordseo="oxford-astrazeneca" source="Orion">Oxford-AstraZeneca</keyword> vaccine. Cutting down fears of a more deadly new variant, she said that viruses tend to "become less virulent as they circulate" through the population, Daily Mail reported. "There is no reason to think we will have a more virulent version of SARS-CoV-2", as "there aren't very many places for the virus to go to have something that will evade immunity but still be a really infectious virus", Gilbert was quoted as saying. The 59-year-old led the team at Oxford University's Jenner institute which created the lifesaving Oxford-AstraZeneca Covid-19 vaccine, the most widely distributed jab in the world. SARS-CoV-2 will eventually become like the coronaviruses which circulate widely and cause the common cold, Gilbert said. "We already live with four different human coronaviruses that we don't really ever think about very much and eventually SARS-CoV-2 will become one of those," said Gilbert, while speaking at a seminar of the Royal Society of Medicine. "It's just a question of how long it's going to take to get there and what measures we're going to have to take to manage it in the meantime." Gilbert, who specialises in the development of jabs against emerging viruses, also called for funding to help prevent future pandemics, the report said. "We're still trying to raise funds to develop other vaccines that we were working on before the pandemic, against diseases that have caused outbreaks in the past and will cause outbreaks in the future. "We are being financially supported for our ongoing work against Covid... but when we try to return to projects we were working on before coronavirus we're still trying to get funding," she noted. Further, she also said the very rare blood clots linked to the <keyword id="6409874" type="General" weightage="80" keywordseo="astrazeneca" source="Orion">AstraZeneca</keyword> jab have not been seen at the same rates in other parts of the world. Gilbert also suggested that primary work on a tweaked vaccine to combat the Beta variant of the virus only gave a "slightly better" immune response than the original vaccine, when given as a third dose to people who had already had two jabs of the AstraZeneca vaccine, but data is still being collected, the report said. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/ipo-bound-rategain-acquires-germany-based-myhotelshop/articleshow/86454447.cms">IPO-bound RateGain acquires Germany based startup to expands software solutions for hoteliers</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/enterprise/news/google-files-writ-petition-in-delhi-hc-against-cci-over-leak-of-confidential-report/articleshow/86453823.cms">Google files writ petition in Delhi HC against CCI over 'leak' of confidential report</a>

COVID-19 virus likely to get weaker and become a common cold, says Oxford-AstraZeneca vax creator

<ul><li>Former PM Rajiv Gandhi said, “Do not design this office for me but design it for the Prime Minister of India.” </li><li>All working women are constantly challenged because we live parallel lives.</li></ul>I have been asked to speak about my journey as an entrepreneur and a design professional. Let me begin by saying that when I began work as an interior designer and furniture manufacturer in 1971, there were no words such as “entrepreneur” or “branding” or things like Instagram and various other forms of social media that exist today. I became a designer because of family influences and growing in a city like Lucknow which is imbued with tehzeeb and nazakat. I do not think I could have been a designer if I had had parents other than those I was blessed with. They were interested in reading and the acquisition of knowledge. My father believed that books would always remain the central element of civilisation. For us knowledge came from immersive reading, and we were voracious readers. We were always interested in places and peoples. We delighted in reading the atlas and dictionaries. In the last 50 years there have been so many places which were our dream destinations, and which one has now visited……… and many places like Machu Picchu that one has not! Perhaps it is still not too late. Because of our father’s immense love for travel and discovery we saw so much of India. The first heritage site that I ever visited was at the age of nine. That was Mahabalipuram in Tamil Nadu and the Temple of the Tooth and the Botanical Gardens in Kandy in Ceylon. All of these were early influences and have influenced my design sensibilities. I have a very contemporary mindset but one that is also deeply grounded in our own heritage. This is because one has had the good fortune of travelling through the length and breadth of India. Much as one has enjoyed the cultures of other countries, I have a deep and constant curiosity about our own country. All this informs the way I work. As far as design education is concerned, I became a designer by accident – serendipitously so! The study of literature and Hindustani classical music enriched my mindscape. I do not have formal training in design but grew up surrounded by design…….. with my father visiting many auction houses and kabadiwalas in Lucknow. It fills me with quiet pride that, as a woman without any formal training in design, I became the first designer in India, man or woman, to be conferred the <keyword id="25105" type="General" weightage="80" keywordseo="padma-shri" source="Orion">Padma Shri</keyword> in 1992. I was reasonably young to be bestowed this honour and I thought at that time that it would open the floodgates to many more interior designers. I have also had the distinction of being the first architect or designer from India to be invited to give an illustrated talk in 2003, at the National Building Museum in Washington DC. This museum is the most visited museum of architecture in the world. Its atrium is the venue of the first presidential ball after a new president has been sworn in. In 2014, I was appointed Chairperson of the Board School of Planning and Architecture in Bhopal, a National Institute of Excellence. That was also a first! But, if you ask me whether I was working towards breaking these glass ceilings, then the answer would be an emphatic no! These happened along the way, as a natural progression in a career in which one had put in much hard work. In my profession one is as good as one’s last project. That gets one more work and not because they like your face. No client is going to spend millions of dollars commissioning you to design their hotel if they do not believe in your talent and your ability to deliver. <div type="image" title="05 South Drawing Room, Rashtrapati Bhawan, New Delhi" msid="98578011" hostid="261" sizebytes="111308" caption="&amp;lt;p&amp;gt;South Drawing Room, Rashtrapati Bhawan&amp;lt;/p&amp;gt;"></div> From 1985 to 1989, I worked on the restoration and conservation of the Rashtrapati Bhavan and in 1988 to 1989 on Hyderabad House. That was the first time that HH was closed for nine months because it was not just the interior decoration that was attended to but also all the interior architecture and services like air conditioning. I designed both the decrepit courtyards in a Lutyensesque style and restored the gardens in Hyderabad House. As far as British buildings in New Delhi are concerned, I had the great privilege of working in the Prime Minister’s Office and Secretariat in South Block. And am happy to note that it has remained unchanged through the tenures of the last nine Prime Ministers. The primary reason for this was the brief from the former PM, Rajiv Gandhi…… “do not design this Office for me but design it for the Prime Minister of India”. I followed this brief and worked on the building as these I firmly believe belong to the nation. His second brief was that he wanted his executive chair to be the same height as his visitors’ chairs. These are all very telling traits of character. I also designed the official residence of the Prime Minister along with restoring the two buildings that comprise the Indira Gandhi Memorial Museum. In New Delhi one has also designed the interiors of the British Council Building and Library. In my career this has been a landmark project because this is the largest of their 80 institutes worldwide. It was inaugurated in 1992 by HRH the Prince of Wales. When we were presented to him, he had a very interesting conversation with me regarding the buildings on either side of the British Council. He certainly has a keen eye for architecture. <div type="image" title="03 National Assembly Building in Thimpu, Bhutan" msid="98578068" hostid="261" sizebytes="195996" caption="&amp;lt;p&amp;gt;National Assembly Building, Bhutan&amp;lt;/p&amp;gt;"></div> Another landmark building for me in 1989 was the <keyword id="1142396" type="General" weightage="50" keywordseo="parliament-building" source="Orion">Parliament Building</keyword> in Bhutan called the National Assembly Building. For me, this was a completely new area of research. In those days so little was known of the art and architecture of Bhutan and neither were any books available. Immersive travelling through Bhutan, to familiarise myself with its architecture and its arts and crafts became essential. His Majesty’s office appointed as my guide, Dasho Khandu who was a living encyclopaedia on Bhutanese art and architecture. These have been amazing projects of learning for me. I like to deeply research new places and new cultures. So maybe, at the end of the day, I think this profession chose me and one is fortunate as this process of working suits my mindset. In a long design career of 50 years, I had a break in 1998. I had simply fallen off a ladder in the house and had fractured two of my cerebral vertebrae. That is when I decided I would stop designing hotels which I had done for the past almost 30 years. At that point I thought I would just design residences in and around India and not travel out to Egypt, Bhutan, England, Timbuktu, etc. But life had other plans! I went on to design a large residence in Sri Lanka and was commissioned to design a boutique hotel in the old city of Lahore. Sadly, that project was eventually abandoned. When I was in Lahore for their Literary Festival at the end of February this year when I saw this building standing as is, it made me quite nostalgic. Lahore is a beautiful city and the people are very hospitable. Along this design journey many institutions have asked me to come to give illustrated lectures. For the ‘Millennium Book on Delhi’, I was one of the eight contributors who wrote an extended essay on ‘The Planning of New Delhi’. <keyword id="118548" type="General" weightage="50" keywordseo="oxford-university-press" source="Orion">Oxford University Press</keyword>, the publishers of the book have a world-wide reach. That is how the Kennedy School of Government in Harvard University heard of this unknown Indian and invited me to give an illustrated talk. Thus began a parallel career in being a speaker. Since Harvard one has given many lectures in many universities and institutions in the US, the UK and in South East Asia on design, architecture, conservation, literature, on ‘Mughal Jewellery as a Statement of Empire’, world heritage cultural sites in India and on social entrepreneurship. One has always believed that women such as oneself are privileged because we are educated. Never mind that we belong to the working classes! We must, with humility and gratitude, help those that are less fortunate. One has been deeply associated with ‘Satyagyan Foundation’ which was an affiliate of ‘World Literacy Canada’. Based in Varanasi, we have worked in about 400 slum areas and have altogether made 23,000 women literate. One has also been associated with ‘Save a Mother’ which was started by the amazing Dr Shiban Gunju. He has reduced the mortality rate of pregnant women by 93%. One was the founding member and last chairperson of ‘Umang’, an NGO that worked for the betterment of street children. These have been my interests and each has been a milestone. Another milestone was co-authoring ‘The Lucknow Cookbook’ with my mother. It is now in its tenth print run and has been declared a classic by Aleph, the publishers. More recently I produced and edited the large formatted book, ‘Kala - Essays on Contemporary Design Aesthetics’ which was launched in Dubai in 2019 by Sheikh Nahan and in October 2022. It had its first proper launches in Milan and London by Artize of the Jaquar Group. In November 2022, it was launched in New York and most recently in February 2023 at the ‘Lahore Literary Festival’. Every stage in life has its own milestones particularly if one is also a wife, a mother and a grandmother. All working women are constantly challenged because we live parallel lives. For me every project, whether large or small, has been a challenge. It has all added to my body of work and to my learning curve. I have never thought of myself as a woman doing all these things……. I think one creates one’s own benchmark and this is the way one has moved forward. I am still working and writing more books as our daughter, the award-winning architect <keyword id="8435490" type="General" weightage="50" keywordseo="kohelika-kohli" source="Orion">Kohelika Kohli</keyword>, has taken over the business of running K2India. She has just launched her new brand of furniture called KOKO by K2India. One feels justifiably proud that one must have done something right. One gave them the tools of a fine education and took them travelling to broaden their minds. And then left them to follow their own passions. (The writer is an award winning architect and an author)

A Padma Shri winning architect takes us through her journey from Lucknow to Lutyens

As the country awaits the UK's approval to the AstraZeneca-Oxford vaccine before giving nod for Emergency Use Authorisation to its Indian counterpart developed by Pune-based <keyword id="95879" type="ORGANIZATION" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword> (SII), a top European drug official has claimed that the vaccine is not even ready for a conditional approval at the moment. Noel Wathion, number two at the European Medicines Agency, told Belgian newspaper Het Nieuwsblad on Tuesday that the approval for AstraZeneca-Oxford vaccine is still "unthinkable" and Europe is not going to approve the vaccine with "winning formula" for the time being. "They haven't even submitted an application to us yet," Wathion was quoted as saying in the report. The UK aims to start rolling out the British AstraZeneca/Oxford vaccine from January 4. According to Wathion, "The data we have at the moment is not even enough to give the AstraZeneca vaccine a conditional authorisation". "We need additional data about the quality of the vaccine. And after that, the company has to formally apply," Wathion added. Pune-based Serum Institute of India on Monday expressed hope at the possibility of its vaccine called Covishield receiving the regulatory approval in "few days", while emphasising that the company has a massive stockpile of 40-50 million doses. "We have 40-50 million doses of Covishield stockpiled. Once we get regulatory approvals in a few days, it will be down to the government to decide how much they can take and how fast. We will be producing around 300 million doses by July 2021," Serum Institute CEO Adar Poonawalla said during a press conference. India currently has eight Covid-19 vaccine candidates, including three indigenous vaccines, under different stages of clinical trials which could be ready for authorisation in near future. Serum Institute-Oxford's Covishield, Bharat Biotech's Covaxin and Pfizer vaccine are in the fray for emergency use authorisation. The central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with 2 crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with comorbidities. Two days of dry run for the vaccination process was also successfully carried out in four states. SEE ALSO: <a href="https://www.businessinsider.in/india/news/india-detects-14-new-cases-of-uk-covid-19-strain-putting-the-tally-at-20/articleshow/80020163.cms">India detects 14 new cases of mutated COVID-19 strain in UK returnees, putting the tally at 20</a> <a href="https://www.businessinsider.in/business/corporates/news/three-anil-ambani-companies-accused-of-fraud-ten-times-more-than-vijay-mallya/articleshow/80002892.cms">Three Anil Ambani companies have reportedly been accused of fraud by banks⁠ — the amount at stake is nearly ten times more than what Mallya owed</a> <a href="https://www.businessinsider.in/india/news/new-strain-of-uk-covid-19-virus-is-a-lot-more-contagious-warns-indias-health-ministry/articleshow/80011618.cms">The new strain of COVID-19 is a lot more contagious, warns India's Health Ministry</a>

Oxford-AstraZeneca COVID-19 vaccine approval is 'unthinkable', claims European watchdog

<ul><li>University of <keyword id="46985" type="COMPANY" weightage="20" keywordseo="Oxford">Oxford</keyword> and <keyword id="95879" type="ORGANIZATION" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword> has started human trials of a new experimental COVID-19 vaccine in Australia. </li><li>SpyBiotech, a UK company created by researchers from Oxford in 2017, has designed the vaccine shot, <a href="https://www.bloomberg.com/news/articles/2020-09-08/new-covid-19-vaccine-from-oxford-begins-early-stage-human-trials?srnd=premium-asia">reported Bloomberg.</a></li><li>This is the second potential coronavirus vaccine from Oxford under trial.</li><li>The Serum Institute of India — which is running the phase I/II trials of SpyBiotech’s shot — is soon going to enrol hundreds of participants. </li></ul>University of Oxford and Serum Institute of India has started human trials of a new experimental COVID-19 vaccine in Australia. SpyBiotech, a UK company created by researchers from Oxford in 2017, has designed the vaccine shot, <a href="https://www.bloomberg.com/news/articles/2020-09-08/new-covid-19-vaccine-from-oxford-begins-early-stage-human-trials?srnd=premium-asia">reported Bloomberg. </a> According to Sumi Biswas, CEO SpyBiotech, the Serum Institute of India — which is running the phase I/II trials of SpyBiotech’s shot — is going to enrol hundreds of participants in the future. “The vaccine uses a virus-like particle from the Hepatitis B antigen as a carrier, employing the company’s proprietary SpyCatcher/SpyTag “superglue” technology to attach the coronavirus spike protein to induce an immune response,” Biswas told Bloomberg in an interview. She further added,” The virus-like-particle has been used for decades in a licensed vaccine against Hepatitis B. SpyBiotech’s technology allows antigens to be bonded to virus-like-particles in a way that enhances stability and effectiveness.” SpyBiotech has reached an exclusive licensing deal with the Serum Institute of India. This is the second potential coronavirus vaccine from Oxford under trial. Oxford-Astrazeneca coronavirus vaccine candidate — ChAdOx1-S — is the most advanced vaccine candidate against COVID-19. ChAdOx1-S is under a Phase III trial in the US. Oxford is likely to end the human trials by November<a href="https://www.livemint.com/news/india/oxford-covid-19-vaccine-human-trials-to-end-by-november-mass-production-from-early-2021-11597314049068.html"> and begin production from early 2021</a>. Oxford has struck a deal with pharma giant Astra Zeneca to mass-produce the vaccine — and provide about 2 billion doses to the world if this trial is successful. SEE ALSO: <a href="https://www.businessinsider.in/india/news/workation-new-trend-in-travel-as-indians-find-unique-new-settings-for-work-from-home/articleshow/77990457.cms">Workation – From private villa at the beach to a pool with a view, Indians are finding unique new settings for ‘work from home’</a>

Oxford and Serum Institute of India begin human trials of a new COVID-19 vaccine in Australia

A nationwide change will take place in the higher education system, especially in undergraduate courses as language will cease to be a barrier in BA, B.Com, and B.Sc courses. Students will be able to graduate in their mother tongue. In view of the same, preparations have begun to make the course books available in languages like Bengali, Gujarati, Kannada, Malayalam, Marathi, Odia, Tamil and Telugu among others. The <keyword id="56459" type="General" weightage="50" keywordseo="university-grants-commission" source="Orion">University Grants Commission</keyword> (<keyword id="44171" type="General" weightage="100" keywordseo="ugc" source="Orion">UGC</keyword>), under an initiative by the <keyword id="10025694" type="General" weightage="50" keywordseo="union-ministry-of-education" source="Orion">Union Ministry of Education</keyword>, is engaging with publishers to translate English textbooks to various Indian languages. Pearson India, Narosa Publishers, Viva Books, S. Chand Publishers, Vikas Publishing, New Age Publishers, Mahavir Publications, Universities Press and Taxmann Publications are some of the major publications involved in the process. Along with these, representatives of <keyword id="118548" type="General" weightage="50" keywordseo="oxford-university-press" source="Orion">Oxford University Press</keyword>, Orient Blackswan and Elsevier also participated in the high-level meeting. The UGC recently held discussions with representatives of Wiley India, Springer Nature, Taylor &amp; Francis, Cambridge University Press India, Cengage India and McGraw Hill, India on bringing out undergraduate English textbooks in Indian languages. UGC, as a part of NEP 2020, is working towards getting the most popular textbooks translated for UG programmes in higher education institutions across the country in the 12 Indian languages. UGC Chairman Professor M. Jagadesh Kumar told IANS that the <keyword id="6355822" type="General" weightage="80" keywordseo="commission" source="Orion">Commission</keyword> will act as a nodal agency to provide help and support to the publishers with regard to identification of textbooks, translation tools and editing experts so that the books can be made affordable in the digital format. He added that the Commission will proceed further in two ways, wherein popular textbooks of the programmes will be identified and translated and simultaneously, Indian authors will be encouraged to write the textbooks in Indian languages for non-technical subjects. Kumar was all praise for the publishers who participated in the mission and said that the Commission intends to get several books translated within six to twelve months, for which it has constituted an apex committee to prepare a road map and work towards the goal. Kumar said that the focus will be on the translation of existing textbooks which will later be extended to postgraduate programmes. SEE ALSO: <a href="https://www.businessinsider.in/thelife/personalities/news/i-am-glad-i-fd-up-so-much-in-life-that-it-is-content-now-says-ankur-warikoo/articleshow/96282722.cms">I am glad I F**%*D up so much in life that it is content now says Ankur Warikoo</a> <a href="https://www.businessinsider.in/careers/news/tech-layoffs-surpass-great-recession-levels-set-to-get-worse-in-early-2023/articleshow/96314678.cms">Tech layoffs surpass Great Recession levels, set to get worse in early 2023</a>

UGC prepares ground for Bachelor's exams in 12 Indian languages

<ul><li>Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the <keyword id="46985" type="COMPANY" weightage="20" keywordseo="Oxford">Oxford</keyword> COVID-19 vaccine candidate in the country</li><li>SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events. </li><li>The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford COVID-19 vaccine candidate till further orders. </li></ul>Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford COVID-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial. The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be "scrupulously" followed by Serum Institute of India (SII). SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events. The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford COVID-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of ''an unexplained illness'' in a participant in the study. On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine have resumed in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe. SII, which has partnered with AstraZeneca for manufacturing the vaccine candidate for COVID-19, on Tuesday submitted the recommendations of the Data and Safety Monitoring Board (DSMB), UK and DSMB, India, and requested for permission to restart enrolment in the clinical trial. According to Tuesday's order issued by DCGI, the DSMB, UK, recommended that the investigators recommence all immunization in their clinical trials subject to certain conditions. DSMB, India, also has recommended to continue the study and enroll the remaining participants in the clinical trial as per protocol subject to certain conditions. According to the order, SII has submitted revised participant information sheet, revised informed consent form and additional safety monitoring plan for the evolved participants. The Pune-based firm has also submitted a summary of safety follow up of seven days post first vaccination, stating that no serious adverse events were experienced by any of the subjects till the date of the reporting, and the reported adverse events were stated to be mild, resolved on their own and did not have any sequale. "In view of the above, I Dr V G Somani, Drugs Controller General of India, Central Licensing Authority, after careful examination of your reply and the recommendations of the DSMB in India and in UK revoke herewith the order dated September 11 issued under Rule 30 of the New Drugs and Clinical Trials Rules, 2019. "You may recommence the clinical trial as recommended by DSMB, India, as per already approved protocol and the provisions laid down under the New Drugs and Clinical Trial Rules, 2019, subject to the conditions mentioned," the order said. SEE ALSO: <a href="https://www.businessinsider.in/science/news/bill-gates-says-the-pandemic-wiped-out-25-years-of-vaccine-progress-in-25-weeks/articleshow/78117898.cms">Bill Gates says the pandemic wiped out 25 years of vaccine progress in 25 weeks</a> <a href="https://www.businessinsider.in/education/news/uks-new-visa-rules-make-it-easier-for-international-students-to-study-and-work-now/articleshow/78127748.cms">UK’s new visa rules make it easier for international students to study and work now</a>

Serum Institute of India can resume clinical trial of Oxford COVID-19 vaccine, says DCGI

Geneva, The <keyword id="43588" type="COMPANY" weightage="20" keywordseo="World-Health-Organization">World Health Organization</keyword> (WHO) has listed two versions of the AstraZeneca/Oxford Covid-19 vaccine for emergency use including the one produced by the <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword>. The other version is produced by AstraZeneca-SKBio (<keyword id="105814" type="LOCATION" weightage="20" keywordseo="Republic-of-Korea">Republic of Korea</keyword>), the WHO said on Monday. The approval of these vaccines means giving the green light for them to be rolled out globally through COVAX. It also allows countries to expedite their own regulatory approval to import and administer Covid-19 vaccines. "Countries with no access to vaccines to date will finally be able to start vaccinating their health workers and populations at risk, contributing to the COVAX Facility's goal of equitable vaccine distribution," Mariangela Simao, WHO Assistant-Director General for Access to Medicines and Health Products, said in a statement. 'But we must keep up the pressure to meet the needs of priority populations everywhere and facilitate global access. To do that, we need two things -- a scale-up of manufacturing capacity, and developers' early submission of their vaccines for WHO review." In the case of the two AstraZeneca/Oxford vaccines, WHO assessed the quality, safety and efficacy data, risk management plans and programmatic suitability, such as cold chain requirements. The process took under four weeks. The AstraZeneca/Oxford product is a viral vectored vaccine called ChAdOx1-S (recombinant). It is being produced at several manufacturing sites, as well as in the Republic of Korea and India. ChAdOx1-S has been found to have 63.09 per cent efficacy and is suitable for low- and middle-income countries due to easy storage requirements. The WHO earlier approved the Pfizer-BioNTech Covid-19 vaccine for emergency use. --IANS gb/in

You Searched For "Oxford Institute" and got 13 results

Despite the hype, AI tools like ChatGPT remain dormant in daily use, shows global survey

Kunal Kambli

Explained: Can consuming Omega-3 supplements really help reduce aggressive behaviour?

Ashmita Gupta

This Amritsar resident got into Oxford, Columbia, Cornell, and 10 major international programs with over Rs. 1.6 crore in scholarships! She shares 5 tips for fellow applicants

Ashmita Gupta

DGCI allows Serum Institute to export malaria vaccine to UK

PTI

AstraZeneca continues to face legal action even after withdrawing its COVID vaccine! Know all about it here

Kunal Kambli

Tax-friendly destinations: A guide to the world's lowest taxes countries

IANS

COVID-19 virus likely to get weaker and become a common cold, says Oxford-AstraZeneca vax creator

IANS

A Padma Shri winning architect takes us through her journey from Lucknow to Lutyens

Sunita Kohli

Oxford-AstraZeneca COVID-19 vaccine approval is 'unthinkable', claims European watchdog

IANS

Oxford and Serum Institute of India begin human trials of a new COVID-19 vaccine in Australia

BI India Bureau

UGC prepares ground for Bachelor's exams in 12 Indian languages

IANS

Serum Institute of India can resume clinical trial of Oxford COVID-19 vaccine, says DCGI

PTI

WHO approves AstraZeneca-Oxford's COVID-19 vaccines for emergency use

IANS

Popular Keywords

Buying Guides